The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Molecular Barcoding To Understand Clonal Dynamics In The Initiation, Maintenance And Progression Of Acute Myeloid Leukemia (AML) At Single Cell Resolution
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Acute myeloid leukaemia (AML) is a blood cancer with low rates of long-term survival. Understanding the ways that AML adapts in the face of treatment will allow us to design treatment that prevents resistance to, and relapse following, treatment. This project will use a new technique called molecular barcoding to allow us to see the genetic and non-genetic changes that occur in each individual leukaemia cell over time in order to determine the mechanisms that underpin resistance to treatment.
Myelodysplastic syndromes (MDS) are disorders of blood-forming stem cells characterised by low blood counts and progression to acute leukaemia. Epigenetics refers to changes in gene expression without changing the underlying DNA sequence. More than half of MDS have mutation/s in epigenetic regulators, providing evidence that epigenetics is an important contributor to the disease. The goal of this project is to better understand how epigenetics contribute to MDS and discovery of new therapies.
Evaluation Of Optimal Pharmacologic Haemodynamic Support Strategies In Patients Presenting With Shock
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Shock is one of the most challenging clinical management scenarios experienced by clinicians. It is a syndrome characterised by an imbalance of oxygen delivery and demand particularly in vital organs. Despite the advances in current treatment strategies for patients with shock, there is still significant morbidity and mortality associated with this syndrome. It is the goal of my PhD to develop improved treatment pathways for patients with shock in order to improve their clinical outcomes.
Targeting Transcriptional Addiction For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
.Tumours driven by the oncogene “Myc” are difficult to treat and an effective means to directly target Myc using small molecules has proven elusive. We have discovered that Myc-dependent tumours are dependent on their ability to globally amplify gene expression through a mechanism that involves the CDK9 enzyme and possibly other related enzymes. I will test the effectiveness of targeting CDK9 in a range of tumours with a Myc dependency, both alone and in combination with other small molecules.
Urine Proteomics As A New Diagnostic Approach For Cardiovascular Risk And As A Discovery Tool For Novel Pathomechanisms In Atherosclerotic Disease
Funder
National Health and Medical Research Council
Funding Amount
$69,500.00
Summary
Atherosclerosis (hardening of blood vessels) followed by blockage is the leading cause of death due to heart attacks and strokes. Up until now there has been no simple tests to predict this reliably.The outcome of this project will give us a better understanding of atherosclerosis and provide a simple non-invasive urine test to detect atherosclerosis which would lend clinicians the opportunity to intervene early.
Risks Of Using A Central Venous Catheter For Haemodialysis In Australia And Opportunities For Improvement
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Patients with permanent or temporary severe kidney failure require dialysis treatment to remain alive and well. Commonly this is performed using a catheter (plastic tube) inserted into a large vein of the body. The use of these catheters, while life saving, is prone to complications. By assessing health data from multiple sources, this project will provide an understanding of the frequency and risk factors for such complications, and improve the lives of patients requiring such treatment.
A New Therapeutic Monoclonal Antibody Targeting CD302 In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will develop a new antibody treatment for Acute Myeloid Leukaemia. Antibody treatments help the body to attack the leukaemia using its immune system. The prognosis of this leukaemia is poor. Our current treatments use high dose chemotherapy and sometimes a stem cell transplant. Many patients cannot have the current therapy due to their age or other medical problems. A new antibody therapy may be used on its own or with other therapies to help more patients achieve remission.
Smartphone Based Secondary Prevention Program For Patients With Acute Coronary Syndromes: A Randomised Control Trial
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Patients at the highest risk of premature death, heart attacks and re-hospitalization are those with known coronary heart disease. Secondary prevention strategies and cardiac rehabilitation are under-utilised in clinical practice. We aim to close this treatment gap by establishing the role of a smartphone based secondary prevention program in patients who have experienced a heart attack. Our innovative model of care may empower patients to optimise their cardiac health.
An Investigation Into ACE2 As A Molecular And Genetic Link To Human Coronary Artery Disease
Funder
National Health and Medical Research Council
Funding Amount
$90,183.00
Summary
Coronary artery disease (CAD) is a leading cause of death but remains underdiagnosed so better tests are needed. We plan to perform a simple, new blood test in those with and without CAD. Our theory is that blood levels will be significantly increased only in those with CAD. If our theory is confirmed, this test may then be used to better predict those with CAD even before they develop symptoms. It will allow provision of early prevention strategies which will likely reduce complications of CAD.
Chronic Oral Graft-versus-host Disease: Clinical Risk Factors, Biochemical Markers Of Disease Activity And Novel Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$134,184.00
Summary
Chronic graft-versus-host disease (GVHD) is a serious complication of bone marrow transplantation. The oral cavity is often affected. Aims: 1.Identify and validate risk factors for oral GVHD 2.Assess if specific salivary components reflect disease activity 3.Trial novel therapeutic for GVHD-associated dry mouth Saliva testing may offer a non-invasive method to monitor oral GVHD. Also, new and effective topical agents are greatly needed and will improve therapeutic options in oral GVHD